Condition (MeSH)
Medulloblastoma
ClinicalTrials.gov lists 314 trials for Medulloblastoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 53.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
314 of the 314 trials are tagged with Medulloblastoma itself; the rest are tagged with a narrower condition beneath it.
When did Medulloblastoma trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 16
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 17 |
| 2025 | 10 |
| 2024 | 10 |
| 2023 | 6 |
| 2022 | 11 |
| 2021 | 11 |
| 2020 | 12 |
| 2019 | 14 |
| 2018 | 14 |
| 2017 | 16 |
Showing 10 of 34 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 20 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 31 trials still running at the 2026-10-09 snapshot; registered median of 54 months across 205 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Medulloblastoma trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 129 |
| Phase 1/2 | 27 |
| Phase 2 | 81 |
| Phase 2/3 | 2 |
| Phase 3 | 13 |
| Phase 4 | 2 |
| Not applicable | 23 |
| Observational | 35 |
| Expanded access | 2 |
How many Medulloblastoma trials are recruiting? (11)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 12 |
| Recruiting | 37 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 31 |
| Available | 1 |
Showing 5 of 11 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Medulloblastoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 53 |
| Children's Oncology Group | 18 |
| Pediatric Brain Tumor Consortium | 16 |
| Novartis Pharmaceuticals | 7 |
| National Institutes of Health Clinical Center (CC) | 6 |
Which drugs are being tested for Medulloblastoma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 34 |
| Irinotecan | 13 |
| Thiotepa | 11 |
| TOPOTECAN | 9 |
| Melphalan | 8 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 32 |
| Etoposid | 26 |
| Filgrastime (G-CSF) | 25 |
| or carboplatin | 21 |
| Cisplatin 1 | 19 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Medulloblastoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil count decreased | 65 | 12 |
| Febrile neutropenia | 51 | 12 |
| Vomiting | 48 | 20 |
| Seizure | 44 | 22 |
| Platelet count decreased | 39 | 12 |
Showing 5 of 10 adverse events.
Which publications cover Medulloblastoma? (137)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors. | Acta neuropathologica communications | 2025 | Yes |
| Evolving Biology and Therapy of WNT-Activated Medulloblastoma. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | Yes |
| Treatment of Medulloblastoma in the Adolescent and Young Adult Population: A Systematic Review. | Journal of adolescent and young adult oncology | 2025 | Yes |
| Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours: a prospective, multicentre study. | Acta neurochirurgica | 2025 | Yes |
| Preoperative 11 C-Methionine PET-MRI in Pediatric Infratentorial Tumors. | Clinical nuclear medicine | 2024 | Yes |
Showing 5 of 137 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Medulloblastoma | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Medulloblastoma | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Medulloblastoma | Annual incidence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Medulloblastoma | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Medulloblastoma | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Medulloblastoma | 616 | Exact | Orphadata Science knowledge files, Product 1 |
| Medulloblastoma | 616 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.